Blog

Credibly reintermediate backend ideas for cross-platform models. Continually reintermediate integrated processes through technically sound intellectual capital.
US drug supply chain alternative to China might run through Canada, Latin America

Excerpt: Centre for Strategic and International Studies panellists from Canada, Mexico, Brazil and Colombia discuss speeding pharmaceutical production and trade with US About 80 per cent of all fine chemicals come from China, according to one estimate, leading to a medical supply chain vulnerability   Article Summary: Representatives of Canada and three Latin American nations...

Pfizer and Valneva enter into an equity subscription agreement and update the terms of the collaboration agreement for Lyme disease vaccine candidate VLA15.

Excerpt Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022   Article Summary Valneva announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As part of the Equity Subscription...

ABVC Biopharma Submit Phase II Study to the HREC

Excerpt ABVC Biopharma, Inc. a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). Article Summary If the submission is received, HREC approval will lead to a Clinical Trial Notification (CTN) submission to...

Impressive Trial Results for Propanc Biopharma with Novel Cancer Treatment

Excerpt Victoria’s Propanc Biopharma Inc. , a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the results from a small trial of just 18 rectal cancer patients in complete remission using an immunotherapy called dostarlimab are “impressive,” whilst acknowledging there’s more work to be done.  Article Summary...

Medigen Seeks Therapeutic Goods Administration (TGA) Approval for COVID-19 Vaccine

Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine, the pharmaceutical company said in a filing with the Taipei Exchange yesterday. Article Summary The company yesterday delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say when the regulator...